1 | 1 | Dubiley and Shogentsukova, 1973 (1) [18] | USSR (Russian) | 2000 | Adults (21–52) | 45 (mild asthma) | FEV1/VC | 71.9±7.4 to 88.4±2.7 | +16.5 | +2.96 | 8 weeks; standard deviation recalculated from reported standard error | Low |
| 2 | Dubiley and Shogentsukova, 1973 (2) [18] | USSR (Russian) | 2000 | Adults (21–52) | 70 (moderate asthma) | FEV1/VC | 68.7±10.0 to 80.4±3.3 | +11.7 | +1.57 |
| 3 | Dubiley and Shogentsukova, 1973 (3) [18] | USSR (Russian) | 2000 | Adults (21–52) | 35 (severe asthma) | FEV1/VC | 64.0±5.3 to 71.4±7.1 | +7.4 | +1.18 |
2 | 4 | Kolesar et al., 1977 [19] | Czechoslovakia (Slovak) | 1800 | Adults (27–39) | 15 | FEV1 % pred | 67.1±6.6 to 69.9±7.3 | +2.8 | +0.40 | 2 weeks; data extracted from a graphical presentation | Very low |
3 | 5 | Boner et al., 1985 [20] | Italy (English) | 1756 | Children (7–14) | 14 | FEV1 % pred | 65.4±10.8 to 82.5±17.2 | +17.1 | +1.19 | 8 weeks | Very low |
4 | 6 | Bobokhodzhaev and Shirinskii, 1990 (1) [21] | USSR (Russian) | 1960 | Adults (21–56) | 20 (atopic asthma) | FEV1/VC | 54.3±10.3 to 63.2±17.4 | +8.9 | +0.62 | 4 weeks | Low |
| 7 | Bobokhodzhaev and Shirinskii, 1990 (2) [21] | USSR (Russian) | 1960 | Adults (21–56) | 24 (nonatopic asthma) | FEV1/VC | 54.1±10.3 to 75.1±23.5 | +21 | +1.16 |
5 | 8 | Brimkulov, 1991 (1) [22] | USSR (Russian) | 3200 | Adults (18–58) | 38 (mild asthma) | FEV1 % pred | 74.9±5.5 to 86.4±7.4 | +11.5 | +1.76 | 4 weeks; standard deviation recalculated from reported standard error | High |
| 9 | Brimkulov, 1991 (2) [22] | USSR (Russian) | 3200 | Adults (18–58) | 94 (moderate asthma) | FEV1 % pred | 64.5±17.2 to 73.3±18.0 | +8.8 | +0.50 |
6 | 10 | Piacentini et al., 1993 [23]# | Italy (English) | 1756 | Children (10.6±1.7) | 20 | FEV1 % pred | 98.0±24.0 to 103.0±34.0 | +5.0 | +0.17 | 2 weeks; data extracted from a graphical presentation | Low |
7 | 11 | Simon et al., 1994 [24] | Switzerland (English) | 1560 | Children (8–15) | 14 | FEV1 % pred | 95.7±9.7 to 104.0±14.7 | +8.3 | +0.67 | 5 weeks | Low |
8 | 12 | Allegra et al., 1995 [11] | Italy and Nepal (English) | 4559 and 5050 | Adults (23–48) | 11 | FEV1 % pred | 102.7±20.4 to 104.8±20.1 | +2.1 | +0.10 | 1 week | Low |
9 | 13 | Boner et al., 1995 (1) [25] | Italy (English) | 1756 | Children (6–14) | 13 (patients on budesonide) | FEV1 % pred | 89.9±9.9 to 99.5±10.7 | +9.6 | +0.93 | 6 weeks | Low |
| 14 | Boner et al., 1995 (2) [25] | Italy (English) | 1756 | Children (6–14) | 7 (patients on placebo) | FEV1 % pred | 92.9±6.5 to 95.0±9.7 | +2.1 | +0.25 |
10 | 15 | van Velzen et al., 1996 [12] | Switzerland (English) | 1560 | Children (10–18) | 16 | FEV1 % pred | 92.1±23.2 to 97.0±20.4 | +4.9 | +0.22 | 4 weeks; standard deviation recalculated from reported standard error | Low |
11 | 16 | Kokov, 1996 [26] | Russian Federation (Russian) | 1850 | Children (9–15) | 68 | FEV1 % pred | 74.7±28.9 to 83.4±23.1 | +8.7 | +0.33 | 3 weeks; standard deviation recalculated from reported standard error; study identified from www.elibrary.ru | High |
12 | 17 | Valletta et al., 1997 [27]# | Italy (English) | 1756 | Children (9–13) | 14 | FEV1 % pred | 82.0±16.0 to 85.0±14.0 | +3.0 | +0.20 | 4 weeks; data extracted from a graphical presentation | Low |
13 | 18 | Grootendorst et al., 2001 [28] | Switzerland (English) | 1560 | Children (12–18) | 18 | FEV1 % pred | 85.6±18.9 to 94.8±17.6 | +9.2 | +0.50 | 10 weeks; standard deviation recalculated from reported standard error | Low |
14 | 19 | Peroni et al., 2002 [29] | Italy (English) | 1756 | Children (7–13) | 18 | FEV1 % pred | 100.5±15.3 to 102.0±12.3 | +1.5 | +0.11 | 12 weeks; standard deviation recalculated from reported standard error | Low |
15 | 20 | Straub et al., 2004 [30]# | Switzerland (English) | 1560 | Children (4–14) | 48 | FEV1 % pred | 105.1±15.9 to 107.0±18.0 | +1.9 | +0.11 | 4 weeks; mean±sd recalculated from the reported median (95% CI) | Moderate |
16 | 21 | Louie and Pare, 2004 [31] | Nepal (English) | 4100 | Adults (24±16) | 5 | PEFR | 558±43 to 482±42 | −76¶ | −1.79 | 2 weeks | Low |
17 | 22 | Peroni et al., 2009 [32] | Italy (English) | 1756 | Children (7–14) | 22 | FEV1 | 2.75±0.70 to 2.78±0.61 | +0.03+ | +0.05 | 4 weeks; standard deviation recalculated from reported standard error | Low |
18 | 23 | Huismans et al., 2010 [33] | Nepal (English) | 6410 | Adults (39±9) | 24 | FEV1 % pred | 104.0±13.0 to 99.0±12.0 | −5.0 | −0.40 | 4 weeks | Low |
19 | 24 | Rijssenbeek-Nouwens et al., 2012 (1) [34] | Switzerland (English) | 1560 | Adults (41.5±14.5) | 92 (sensitised to HDM) | FEV1 % pred | 88.4±20.4 to 94.2±20.1 | +5.8 | +0.29 | 12 weeks | High |
| 25 | Rijssenbeek-Nouwens et al., 2012 (2) [34] | Switzerland (English) | 1560 | Adults (48±15.3) | 45 (nonsensitised to HDM) | FEV1 % pred | 86.5±26.2 to 92.8±23.1 | +6.3 | +0.26 |
20 | 26 | Seys et al., 2013 [35] | Argentina (English) | 6965 | Adults (39.6±11.3) | 18 | FEV1 % pred | 90.2±12.0 to 98.0±14.0 | +7.8 | +0.60 | 2 weeks; data extracted from a graphical presentation | Low |
21 | 27 | Verkleij et al., 2013 (1) [14]# | Switzerland (English) | 1560 | Children (7–18) | 51 (Netherlands Clinic Davos) | FEV1 % pred | 105.8±3.4 to 106.1±13.7 | +0.3 | +0.03 | 6 weeks | Moderate |
| 28 | Verkleij et al., 2013 (2) [14]# | Switzerland (English) | 1560 | Children (7–18) | 48 (High Altitude Clinic Davos) | FEV1 % pred | 99.4±14.0 to 99.7±15.5 | +0.3 | +0.02 |